Proprietary Therapeutic Pipeline
Undisclosed
DiscoveryActive
Key Facts
About Excelsior Sciences
Excelsior Sciences is a private, pre-revenue biotech founded in 2018 that is developing an automated, AI-integrated platform for small molecule discovery and manufacturing. Its core innovation is 'Blocc Chemistry,' which uses standardized, machine-ready building blocks to enable rapid, iterative, closed-loop synthesis and testing. Backed by $95M in Series A funding from top-tier investors, the company is building a proprietary therapeutic pipeline while also pursuing collaborations to transform how molecules are made across multiple industries.
View full company profileOther Undisclosed Drugs
| Drug | Company | Phase |
|---|---|---|
| Preclinical ISAC 1 | Bolt Biotherapeutics | Preclinical |
| Preclinical ISAC 2 | Bolt Biotherapeutics | Preclinical |
| ART12.11 | Artelo Biosciences | Preclinical |
| Novel Vaccines | MSD | Development |
| SLS-009 | Seelos Therapeutics | Discovery |
| Technosphere Platform (New Formulations) | MannKind | Discovery/Preclinical |
| Measovir®-based Prophylactic Vaccine (with Unither) | Oncovita | Research/Pre-clinical |
| Internal sdAb Discovery Program | NanoTag Biotechnologies | Discovery |
| NB-701 | Nerai Biosciences | Discovery |
| Undisclosed Therapeutic Program(s) | Bright Cell | Clinical Trial (Phase unspecified) |
| Biosimilars Pipeline | Intelligent Therapeutics | Pre-clinical/Development |
| Therapeutic Programs | Agathos Biologics | Pre-clinical |